Skip to main content
SpringerLink
Log in

Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are common gastrointestinal (GI) disorders. Current treatment options, either prescription or nonprescription medications, have limited efficacy in a subset of patients. There is significant demand for more efficacious medications for the treatment of CC and IBS-C. Linaclotide, a secretagogue, has a novel mechanism of action designed to treat patients with CC and IBS-C. It has a low oral bioavailability with negligible systemic side effects, and it acts locally in the intestinal lumen. In several clinical trials, in health and disease, linaclotide has demonstrated durable efficacy and safety in CC and IBS-C. Linaclotide received approval by the Federal Drug Administration in August 2012 to treat chronic idiopathic constipation and IBS-C.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99:750–759.

    Article  PubMed  Google Scholar 

  2. Choung RS, Locke GR, 3rd, Schleck CD, et al. Cumulative incidence of chronic constipation: a population-based study 1988–2003. Aliment Pharmacol Ther. 2007;26:1521–1528.

    Article  PubMed  CAS  Google Scholar 

  3. Vazquez Roque M, Camilleri M. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev Gastroenterol Hepatol. 2011;5:301–310.

    Article  PubMed  Google Scholar 

  4. Everhart JE, Go VL, Johannes RS, et al. A longitudinal survey of self-reported bowel habits in the United States. Dig Dis Sci. 1989;34:1153–1162.

    Article  PubMed  CAS  Google Scholar 

  5. Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958 to 1986. Dig Dis Sci. 1989;34:606–611.

    Article  PubMed  CAS  Google Scholar 

  6. Martin BC, Barghout V, Cerulli A. Direct medical costs of constipation in the United States. Manag Care Interface. 2006;19:43–49.

    PubMed  Google Scholar 

  7. Bongers ME, Benninga MA, Maurice-Stam H, et al. Health-related quality of life in young adults with symptoms of constipation continuing from childhood into adulthood. Health Qual Life Outcomes 2009;7:20.

    Article  PubMed  Google Scholar 

  8. Wang JP, Duan LP, Ye HJ, et al. [Assessment of psychological status and quality of life in patients with functional constipation]. Zhonghua Nei Ke Za Zhi. 2008;47:460–463. In Chinese.

    PubMed  Google Scholar 

  9. Sun SX, Dibonaventura M, Purayidathil FW, et al. Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci. 2011;56:2688–2695.

    Article  PubMed  Google Scholar 

  10. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108–2131.

    Article  PubMed  Google Scholar 

  11. Spiegel BM. The burden of IBS: looking at metrics. Curr Gastroenterol Rep. 2009;11:265–269.

    Article  PubMed  Google Scholar 

  12. Vazquez Roque M, Camilleri M. Velusetrag. Drugs Future. 2011;36:447–454.

    CAS  Google Scholar 

  13. Camilleri M, Kerstens R, Rykx A, et al. A placebocontrolled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–2354.

    Article  PubMed  CAS  Google Scholar 

  14. Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011;106:2154–2164.

    Article  PubMed  CAS  Google Scholar 

  15. Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52:375–414.

    PubMed  CAS  Google Scholar 

  16. Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010;86:760–765.

    Article  PubMed  CAS  Google Scholar 

  17. Harris LA, Crowell MD. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mol Ther. 2007;9:403–410.

    PubMed  CAS  Google Scholar 

  18. Schulz S, Lopez MJ, Kuhn M, et al. Disruption of the guanylyl cyclase-C gene leads to a paradoxical phenotype of viable but heat-stable enterotoxin-resistant mice. J Clin Invest. 1997;100:1590–1595.

    Article  PubMed  CAS  Google Scholar 

  19. Busby RW, Bryant AP, Cordero EA, et al. The molecular target of MD-1100 is guanylate cyclase-C (GC-C), an apical receptor on intestinal epithelial cell. Gastroenterology. 2005;128:A464.

    Google Scholar 

  20. Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol. 2010;649:328–335.

    Article  PubMed  CAS  Google Scholar 

  21. Bryant AP, Busby RW, Cordero EA, et al. MD-1100, a therapeutic agent in development for the treatment of IBS-C, enhances intestinal secretion and transit, decreases visceral pain and is minimally absorbed in rats. Gastroenterology. 2005;128:A464.

    Google Scholar 

  22. Bryant AP, Busby RW, Cordero EA, et al. The characterization of an active metabolite of MD-1100, a therapeutic agent in development for the treatment of IBS-C and chronic constipation. Gastroenterology. 2006;130:T2034.

    Google Scholar 

  23. Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil. 2010;22:312–e384.

    Article  PubMed  CAS  Google Scholar 

  24. Castro JHA, Hughes PA, Martin C, et al. Mechanism of action for linaclotide induced abdominal pain relief. Gastroenterology. 2012;142:S699.

    Google Scholar 

  25. Brady S. Microbia succesfully completes phase IA trial of MD-1100 for IBS-C and other GI disorders. 2005. Available at: http://www.ironwoodpharma.com/newsPDF/2005_05.17.Microbia.IBS.IA.pdf. Accessed Sep 1 2012.

    Google Scholar 

  26. Currie MG, Kurtz CB, Mahajan-Miklos S, et al. Effects of single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects. Am J Gastroenterol. 2005;100:S328.

    Google Scholar 

  27. Kurtz CB, Fitch DA, Busby RW, et al. Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacodynamics in healthy subjects. Gastroenterology. 2006;130:A–26. Abstract 132.

    Google Scholar 

  28. Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007;133:761–768.

    Article  PubMed  CAS  Google Scholar 

  29. Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol. 2009;104:125–132.

    Article  PubMed  CAS  Google Scholar 

  30. Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138:886–895.e1.

    Article  PubMed  CAS  Google Scholar 

  31. Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139:1877–1886.e2.

    Article  PubMed  CAS  Google Scholar 

  32. Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527–536.

    Article  PubMed  CAS  Google Scholar 

  33. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107:1714–1724.

    Article  PubMed  CAS  Google Scholar 

  34. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebocontrolled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107:1702–1712.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA

    Maria I. Vazquez-Roque & Ernest P. Bouras

Authors
  1. Maria I. Vazquez-Roque
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ernest P. Bouras
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ernest P. Bouras.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vazquez-Roque, M.I., Bouras, E.P. Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome. Adv Therapy 30, 203–211 (2013). https://doi.org/10.1007/s12325-013-0012-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-013-0012-9

Keywords

Search

Navigation